J. Zujewski

发表

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

L. Rubinstein, L. Rubinstein, J. Zujewski, 2017, npj Breast Cancer.

A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer

D. Venzon, K. Cowan, J. O’Shaughnessy, 2003, Breast Cancer Research and Treatment.

Tamoxifen and fenretinide in women with metastatic breast cancer

M. Merino, D. Venzon, K. Cowan, 1999, Breast Cancer Research and Treatment.

The 1998 St. Gallen's Consensus Conference: an assessment.

J. Zujewski, E. Liu, 1998, Journal of the National Cancer Institute.

Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.

R. Gray, E. Perez, T. Whelan, 2014, Journal of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference

E. Winer, R. Coombes, A. Buzdar, 2008, Cancer.

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

E. Perez, D. Visscher, J. Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of fenretinide (4-HPR) on dark adaptation.

M. Kaiser-Kupfer, B. Conley, J. Zujewski, 1998, Archives of ophthalmology.

Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.

I. Pastan, M. Gottesman, D. Venzon, 1999, Blood.

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

E. Perez, M. Buyse, S. Paik, 2013, Breast Cancer Research and Treatment.

Gynecologic and hormonal effects of raloxifene in premenopausal women.

D. Venzon, M. Forman, A. Remaley, 2007, Fertility and sterility.

Effects of Raloxifene on Circulating Prolactin and Estradiol Levels in Premenopausal Women at High Risk for Developing Breast Cancer

D. Venzon, S. Prindiville, J. Zujewski, 2006, Cancer Epidemiology Biomarkers & Prevention.

Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry

J. Mulshine, I. Weinberg, E. Jones, 1996, European Journal of Nuclear Medicine.

Transforming growth factors-β are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system

L. Wakefield, K. Flanders, R. Lubet, 2000, Breast Cancer Research.

CNS Metastasis: An Old Problem in a New Guise

J. Aragon-Ching, J. Zujewski, 2007, Clinical Cancer Research.

Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer.

J. Abrams, J. Abrams, J. Zujewski, 1998, Journal of the National Cancer Institute.

The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer

M. Merino, S. Bacharach, J. Carrasquillo, 2002, Breast Cancer Research and Treatment.

Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.

E. Perez, J. Ingle, T. Pisansky, 2009 .

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.

M. Kaiser-Kupfer, M. Merino, D. Venzon, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

L. Rubinstein, W. Barlow, M. Regan, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer

K. Camphausen, J. Parker, K. Hunter, 2010, Breast Cancer Research and Treatment.

Building a Network of Health Professionals for Breast and Cervical Cancer Control in the Andean Region

J. Zujewski, L. Stevens, C. Muha, 2017, Journal of global oncology.

Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low‐income and middle‐income countries

J. Gralow, B. Anderson, J. Zujewski, 2020, Cancer.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.

"Build quality in"--HER2 testing in the real world.

J. Zujewski, 2002, Journal of the National Cancer Institute.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.

M. Merino, D. Venzon, D. Kleiner, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I C linical T rial o f A litretinoin a nd T amoxifen i n Breast C ancer P atients: T oxicity, P harmacokinetic, a nd Biomarker E valuations

M. Merino, D. Venzon, D. Kleiner, 2001 .

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya.

S. Dawsey, S. Sayed, J. Zujewski, 2016, The oncologist.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring stigma as a barrier to cancer service engagement with breast cancer survivors in Kampala, Uganda

D. Rao, J. Zujewski, J. Orem, 2016, Psycho-oncology.

Early Suppressive Effects of Chemotherapy on Recovery of Bone Marrow Megakaryocyte Precursors: Possible Relationship to Platelet Recovery

K. Cowan, J. O’Shaughnessy, J. Zujewski, 1996, Stem cells.

Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).

E. Kohn, L. Minasian, Jung-Min Lee, 2013 .

Patient Advocacy Approaches to Improving Care for Breast and Cervical Cancer in East and Southern Africa

J. Gralow, J. Zujewski, A. Dvaladze, 2020, JCO global oncology.

Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer

Sheila Prindiville, Claudia E. Galbo, D. Venzon, 2008, Cancer Epidemiology Biomarkers & Prevention.

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005)

M. Buyse, S. Paik, Chungyeul Kim, 2010 .

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.

A. Tolcher, D. Venzon, P. Keegan, 1996, Blood.

A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.

D. Venzon, F. Balis, B. Widemann, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

After Breast Cancer Chemotherapy Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells

I. Pastan, M. Gottesman, D. Venzon, 2013 .

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

W. Wilson, S. Steinberg, I. Pastan, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo.

K. Cowan, J. O’Shaughnessy, J. Zujewski, 1997, Blood.

Transduction of hematopoietic stem cells in humans and in nonhuman primates

D. Bodine, T. Soma, J. Zujewski, 1997, Stem cells.

Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells

A. Tolcher, J. O’Shaughnessy, J. Zujewski, 1998, Bone Marrow Transplantation.

Multidisciplinary meeting on male breast cancer: summary and research recommendations.

J. Bergh, W. McCaskill-Stevens, G. Hortobagyi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lori Minasian, Bradford J Wood, E. Kohn, 2014, Journal of the National Cancer Institute.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Jack Cuzick, Lisa McShane, Christos Sotiriou, 2011, Journal of the National Cancer Institute.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Sally Hunsberger, R. Gray, R. Gelber, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Workshop on imaging science development for cancer prevention and preemption.

G. McLennan, C. Tempany, S. Lam, 2006, Cancer biomarkers : section A of Disease markers.

Inflammatory breast cancer: yet another risk of the obesity epidemic?

L. Amiri-Kordestani, J. Zujewski, F. Kamangar, 2013, Journal of the National Cancer Institute.

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

Kevin Camphausen, Mark Sherman, Peter Choyke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

A. Tolcher, K. Cowan, J. O’Shaughnessy, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial

S. Steinberg, R. Altemus, M. Merino, 2003, Annals of Surgical Oncology.

Effect of tamoxifen on mammographic density.

D. Venzon, J. O’Shaughnessy, J. Zujewski, 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Assessing breast cancer risk

Kathleen A. Calzone, K. Calzone, L. Korde, 2004, Postgraduate medicine.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Jong-Hyeon Jeong, Norman Wolmark, Priya Rastogi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow

J. O’Shaughnessy, C. Mackall, J. Zujewski, 1996, British journal of haematology.

Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.

C. Mackall, J. Zujewski, R. Gress, 1997, Blood.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

C. Bowden, R. Nussenblatt, K. Cowan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.

A. Tolcher, K. Cowan, J. O’Shaughnessy, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

M. Ellis, L. Esserman, N. Hylton, 2012, The Lancet. Oncology.

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

M. Ellis, E. Winer, K. Hunt, 2021 .

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

M. Ellis, J. Forbes, S. Jewell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.

J. Zujewski, L. Kamin, 2008, Future oncology.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal therapy of breast cancer.

J. Zujewski, P. Lebowitz, 2003, Current problems in cancer.

Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.

J. Gralow, J. Zujewski, Julie R Gralow, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

Raloxifene and its role in breast cancer prevention

J. Zujewski, J. Eng‐Wong, 2004, Expert review of anticancer therapy.

Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.

D. Venzon, J. Zujewski, S. Perkins, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The needle in the haystack: Application of breast fine‐needle aspirate samples to quantitative protein microarray technology

Kevin Camphausen, Emanuel F Petricoin, Virginia Espina, 2007, Cancer.

Changing Paradigms in Breast Cancer Therapeutics: An Extended Abstract

J. Zujewski, 2015, Medical Principles and Practice.

Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer.

D. Venzon, M. Saif, J. Zujewski, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women

A. Neugut, S. Sayed, J. Zujewski, 2017, Journal of global oncology.

Sentinel lymph node biopsy in the management of ductal carcinoma in situ.

J. Zujewski, J. Eng-Wong, J. Eng‐Wong, 2005, Clinical breast cancer.

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

L. Rubinstein, J. Zujewski, 2017, npj Breast Cancer.

Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention

J. Zujewski, 2002, Environmental and molecular mutagenesis.

Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer

P. Okunieff, S. Steinberg, K. Cowan, 1998, Annals of Surgical Oncology.

Knowledge Summaries for Comprehensive Breast Cancer Control: Feedback From Target Audiences in Kenya

Amanda L. Vogel, J. Zujewski, A. Dvaladze, 2019, Journal of global oncology.

Ductal carcinoma in situ: trends in treatment over time in the US

J. Zujewski, L. Harlan, Jennifer L. Stevens, 2011, Breast Cancer Research and Treatment.

Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy

L. Enewold, A. Geiger, J. Zujewski, 2015, Breast Cancer Research and Treatment.

Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.

D. Venzon, D. Danforth, J. Zujewski, 2006, The Journal of clinical endocrinology and metabolism.

Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

C. Harmon, P. Klein, P. Kushner, 2022, Cancer Research.

Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines

W. Telford, G. Clark, J. Zujewski, 2003, Breast Cancer Research and Treatment.

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

M. Merino, D. Venzon, S. Swain, 2004, Clinical Cancer Research.

Proposal for the use of progression-free survival in unblinded randomized trials.

Boris Freidlin, Robert Gray, Edward L Korn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.

E. Kohn, L. Minasian, S. Prindiville, 2010 .

Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Women’s Empowerment Cancer Advocacy Network (WE CAN) Summits

J. Gralow, J. Zujewski, A. Dvaladze, 2021, JCO global oncology.

Research issues affecting preoperative systemic therapy for operable breast cancer.

D. Berry, M. Ellis, D. Mankoff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.

V. Jordan, J. Zujewski, R. Chatterton, 2006, The Journal of endocrinology.

Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).

E. Kohn, L. Minasian, J. Doroshow, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Triple negative breast cancer: breast cancer research in evolution.

J. Zujewski, S. Hunsberger, J. Eng‐Wong, 2010, Breast disease.

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

E. Perez, W. McCaskill-Stevens, J. Sloan, 2014 .

Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer

C. Harmon, N. Lin, P. Klein, 2021 .

Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal Kenya

S. Sayed, J. Zujewski, T. Wynn, 2019, BMC Public Health.

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2015 .

Knowledge Summaries for Comprehensive Breast Cancer Control

B. Anderson, J. Zujewski, A. Dvaladze, 2017, Journal of global oncology.

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

D. Berry, L. Esserman, O. Olopade, 2013, Clinical Cancer Research.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

R. Gray, J. Sparano, A. Tevaarwerk, 2016 .

Breast cancer in men in the United States

M. Goodman, J. Zujewski, L. Harlan, 2010, Cancer.

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

M. Ellis, J. Forbes, S. Jewell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

J. Olson, M. Ellis, R. Gray, 2015, The New England journal of medicine.

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

L. Esserman, J. Forbes, S. Loi, 2011, The Lancet. Oncology.

A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer.

M. Merino, F. Balis, B. Widemann, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.